| __timestamp | Alkermes plc | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 28427000 |
| Thursday, January 1, 2015 | 4019000 | 37065000 |
| Friday, January 1, 2016 | 2301000 | 41199000 |
| Sunday, January 1, 2017 | 7232000 | 43415000 |
| Monday, January 1, 2018 | 68895000 | 57564000 |
| Tuesday, January 1, 2019 | 52816000 | 68853000 |
| Wednesday, January 1, 2020 | 1946000 | 67229000 |
| Friday, January 1, 2021 | 1020000 | 60932000 |
| Saturday, January 1, 2022 | 393842000 | 74771000 |
| Sunday, January 1, 2023 | 270806000 | 73741000 |
| Monday, January 1, 2024 | 245326000 |
Unleashing insights
In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Alkermes plc and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Alkermes plc's R&D expenses surged by over 3,400%, peaking in 2022 with a remarkable 394 million USD. This reflects a strategic pivot towards aggressive innovation. In contrast, Amphastar Pharmaceuticals maintained a steady increase, with a 163% rise over the same period, reaching 74.8 million USD in 2022. This consistent growth underscores a balanced approach to innovation and stability. The data reveals a fascinating narrative of how two industry players allocate resources to fuel their future growth. As the pharmaceutical landscape evolves, these investment strategies will likely shape their competitive edge and market positioning.
Eli Lilly and Company or Alkermes plc: Who Invests More in Innovation?
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for BeiGene, Ltd. and Alkermes plc
Research and Development Investment: Summit Therapeutics Inc. vs Alkermes plc
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and Alkermes plc
R&D Spending Showdown: Pharming Group N.V. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?